Dan Belsky
speaker
80 appearances
1 recordings
1 series
first heard Jul 2026
last heard 17 Jul
Dan Belsky’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.
Appearances
And what DoHealth observed was that the omega-3 intervention in particular reduced the rate of increase in the grim age, another biomarker developed to predict mortality called PhenoAge, and also the pace of aging biomarker, Dunedin PACE.
There was no effect of vitamin D. There were equivocal effects of exercise.
And while the researchers had anticipated an additive effect of combining those interventions, while there was some evidence for an additive effect on the PhenoAge, there was not across the other markers.
And then the third trial was called COSMOS, was run here in the United States.
And in this case, epigenetic clock analysis was done of a subset of those participants, the ones who remained healthy over the course of the trial.
It's hard to know consequences for disease or certainly mortality.
But what we saw there was that the multivitamin supplementation did slow the ticking rate of the grim age clock, although very slightly.
We can do a lot more with the information we're already collecting.
What your physician is today looking out for is, are you sick?
They're asking, of those measurements that they're taking, is there evidence of a problem?
And what we're seeing in the research that we're doing is that we can go beyond sick, not sick.
we can actually speak to level of risk across a continuum.
And particularly by accumulating serial measurements of that underlying level of risk and mapping trajectories within a patient, which we can do, we can get a lot farther toward prevention than we're able to with the current framework.
Now, the reason that physicians aren't rushing to adopt these new technologies is they're not yet proven.
We don't know that we can scale them up within the context of a healthcare system in the way that we know we can scale up the sick, non-sick.
Do we have demonstration of clinical utility today?
The answer is no.
Do we have a vision of where clinical utility might arise?
I think the answer to that question is yes.
And so here are a couple of different ways in which we might be able to generate that clinical utility.
Showing 41–60 of 80 · page 3 of 4
← Previous
Next →